– USA, PA – Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Carol Schafer to its Board of Directors, bringing more than 25 years of experience in investment banking and equity capital markets and has served as a corporate director for multiple public companies.
“Carol’s financial expertise, strategic insight and understanding of equity markets will greatly benefit Immunome as we continue to expand and advance our pipeline of targeted oncology therapeutics. The Immunome leadership team will draw on her experience as we work to develop best-in-class and first-in-class treatments for cancer patients. We are pleased to welcome her to the Board of Directors,” said hairman and CEO, Dr. Clay Siegall.
About Carol A. Schafer
Carol Schafer currently serves as the Managing Partner of Hyphen Advisors. Additionally, Ms. Schafer currently serves on the Board of Directors of Insmed, Repare Therapeutics, and Kura Oncology, and previously served on the Board of Directors of Five Prime Therapeutics and Idera Pharmaceuticals.
Before Hyphen Advisors, Ms. Schafer served as Vice-Chair of Wells Fargo Securities, where she led the healthcare equity capital markets team and was responsible for originating and executing equity and convertible financings. Before joining Wells Fargo Securities, Ms. Schafer served as VP of Finance and Business Development of Lexicon Pharmaceuticals. Previously, Ms. Schafer served as Managing Director of Equity Capital Markets of JPMorgan Chase working with companies in the healthcare, retail, consumer, and chemical industries.
“I am honored to join Immunome, and I am particularly impressed by the company’s differentiated approaches to developing ADCs and radioligand therapies and its platform for identifying underexplored targets,” said Carol Schafer. “I look forward to collaborating with Immunome’s Board of Directors and management team to advance its ambitious pipeline, realize its strategic goals and maximize its strong financial position.”
Ms. Schafer earned her MBA from New York University, and her BA in mathematics and computer science from Boston College.
About Immunome, Inc.
Immunome is a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies. Our portfolio pursues each target with a modality appropriate to its biology, including radioligand therapies, ADCs, and immunotherapies. We believe that pursuing underexplored targets with appropriate drug modalities leads to transformative therapies. Our proprietary memory B cell hybridoma technology allows for the rapid screening and functional characterization of novel antibodies and targets.
SOURCE: https://immunome.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
